Related Experiment Video
Updated: May 4, 2026
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
Published on: January 17, 2014
Deciphering mechanisms of GPCR compounds against tuberculosis through ferroptosis inhibition using high-throughput
Xiuli Luan1, Chengyu Qian2, Haoran Li2
1Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, PR China; Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, PR China.
Abstract:
Ferroptosis represents a significant mechanism of necrosis during tuberculosis infection and a potential target for host-directed therapy, with G-protein-coupled receptors (GPCRs) modulating this process. This study investigates GPCR-targeting compounds for their capacity to inhibit ferroptosis and their therapeutic potential in tuberculosis. Compounds were evaluated for their ability to inhibit lipid peroxidation via high-throughput screening with the BODIPY 581/591 C11 probe, followed by screening for mycobacterium inhibition. Identified GPCR compounds targeting genes associated with ferroptosis (GFRGs) or tuberculosis (GTRGs) were analyzed using network pharmacology, with shared hub targets subjected to molecular docking and molecular dynamics (MD) simulations. Cellular experiments confirmed the safety, potent anti-ferroptotic activity, and modulation of ferroptosis-related genes in macrophages treated with selected Prazosin hydrochloride. From the GPCR compound Library, 32 compounds were identified that effectively inhibited both lipid peroxidation and Mycobacterium tuberculosis (MTB) infection in macrophages. A total of 446 GFRGs were identified, including 148 GFRDEGs. Among the 19 compounds not previously linked to tuberculosis or ferroptosis, 1314 GTRGs were identified. Six overlapping hub genes were found between GTRGs and GFRDEGs, and molecular docking showed stable interactions (binding scores < -6 kJ/mol) for six compound-target protein pairs. Notably, Prazosin hydrochloride exhibited high stability with MAPK3 in MD simulations and significantly reduced MTB-induced ferroptosis in macrophages. This study underscores the therapeutic potential of GPCR compounds in targeting ferroptosis to inhibit MTB infection, supporting their development as novel anti-tuberculosis therapies. Our comprehensive analysis and elucidation of the molecular mechanisms of these compounds provide a solid theoretical foundation for the development of innovative host-directed treatment strategies against tuberculosis.
